Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 2Other solid neoplasm 1Gynecologic 1

Conditions

Ovarian Neoplasms 2573Uterine Cervical Neoplasms 1693Endometrial Neoplasms 1012Fallopian Tube Neoplasms 730Carcinoma, Ovarian Epithelial 681Breast Neoplasms 676Neoplasms 436Carcinoma, Non-Small-Cell Lung 379Colorectal Neoplasms 372Stomach Neoplasms 302Pancreatic Neoplasms 302Uterine Cervical Dysplasia 273Prostatic Neoplasms 262Lung Neoplasms 250Melanoma 247Neoplasm Metastasis 216Peritoneal Neoplasms 197Carcinoma, Renal Cell 193Sarcoma 190Head and Neck Neoplasms 189Urinary Bladder Neoplasms 187Esophageal Neoplasms 187Recurrence 185Triple Negative Breast Neoplasms 181Uterine Neoplasms 176Vulvar Neoplasms 173Squamous Cell Carcinoma of Head and Neck 168Colonic Neoplasms 162Papillomavirus Infections 153Small Cell Lung Carcinoma 128

Interventions

olaparib 1Paclitaxel 1Carboplatin 1CP protocol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Triple Negative Metastatic Breast Cancer × Gynecologic × Clear all
NCT00516724 2025-04-11

Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel

AstraZeneca

Phase 1 Completed
189 enrolled
BreastGynecologic

Triple Negative Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡